Improving lung cancer treatment by targeting specific immune cells
Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung Cancer
This study is looking at a new way to help people with non-small cell lung cancer by targeting certain immune cells to make cancer treatments work better, and if you join, you might get access to promising new therapies that could improve your health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11115022 on NIH RePORTER |
What this research studies
This research investigates how tumor-associated macrophages (TAMs) in non-small cell lung cancer (NSCLC) can be targeted to enhance the effectiveness of immunotherapy. By inhibiting hedgehog signaling in these immune cells, the study aims to improve the recruitment and function of CD8 T cells, which are crucial for fighting cancer. The research will involve a multi-center phase Ib clinical trial to evaluate the combined effects of hedgehog inhibition and anti-PD-L1 therapy on patients with NSCLC. Patients participating in this research may receive new treatment options that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer who are seeking new treatment options.
Not a fit: Patients with early-stage lung cancer or those who do not have non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promising results in targeting tumor-associated macrophages to enhance cancer immunotherapy, suggesting that this approach may be effective.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Owen, Dwight H. — Ohio State University
- Study coordinator: Owen, Dwight H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.